Additional file 1: of Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial Kim Papp Robert Bissonnette Melinda Gooderham Steven Feldman Lars Iversen Jennifer Soung Zoe Draelos Carla Mamolo Vivek Purohit Cunshan Wang William Ports 10.6084/m9.figshare.c.3627356_D2.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Treatment_of_plaque_psoriasis_with_an_ointment_formulation_of_the_Janus_kinase_inhibitor_tofacitinib_a_Phase_2b_randomized_clinical_trial/4412861 Figure S1. Change from baseline in DLQI through Week 16. Table S1. Serious adverse events by treatment group. Table S2. Number and percent of plasma tofacitinib concentration samples (pre-dose and post-dose) by concentration range – available data mild/moderate - post hoc. Table S3. Summary of plasma tofacitinib pharmacokinetic parameters - available data at week 4 - mild/moderate - post hoc. (DOCX 238 kb) 2016-10-03 05:00:00 Psoriasis Topical Tofacitinib CP-690,550 Physician’s Global Assessment Psoriasis Area and Severity Index PASI Dermatology Life Quality Index Pruritus Itch